Summit Therapeutics PLC logo

Summit Therapeutics PLC(SMMT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$14.15
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SMMT

11/13/2026: SMMT (1-star) is currently NOT-A-BUY. Pass it for now.

Summit Therapeutics is a clinical-stage biotechnology company focused on developing novel oncology medicines, most notably its flagship bispecific antibody, ivonescimab. Its investment story centers on the potential of this lead asset to challenge established standards of care in lung cancer. The company's main strength lies in its focused clinical execution and strategic partnership for a promising molecule. However, significant risks include high concentration on a single asset, the necessity for sustained capital raises to fund late-stage development, and intense competition from major global pharmaceutical players. This stock is best suited for growth-oriented investors who can tolerate high volatility and binary clinical-trial outcomes.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe company offers high growth potential linked to the success of its lead asset, ivonescimab.
Momentum investorStrong fit while signal remains positiveThe stock often reacts aggressively to clinical data updates and regulatory news flow.
Value investorWeak fitThe company is not currently profitable and does not trade on traditional valuation metrics.
Dividend investorWeak fitThe company provides no income to shareholders and is not suitable for dividend-focused strategies.
Low-risk investorWeak fitThe company's reliance on clinical outcomes makes it highly speculative and volatile.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSpeculative biotech stocks often see double-digit daily moves based on trial announcements.
Valuation riskHighCompany valuation is highly dependent on binary clinical outcomes rather than current cash flows.
Competition risk (Immuno-oncology)HighMajor pharmaceutical companies are investing heavily in competing PD-1/VEGF-based therapies.
Business qualityMediumThe company has a focused strategy but lacks the diversified portfolio and scale of mature peers.
Dividend incomeLow / noneNo capital is returned to shareholders; total return is entirely dependent on share price appreciation.
Execution riskHighSuccess depends entirely on achieving positive clinical results and regulatory approval for its lead candidate.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 11.32B USD
Price to earnings Ratio -
1Y Target Price 29.49
Price to earnings Ratio -
1Y Target Price 29.49
Volume (30-day avg) 5.1M shares
Beta -1.52
52 Weeks Range 12.07 - 29.23
Updated Date 11/14/2026
52 Weeks Range 12.07 - 29.23
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.06

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 140.07%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SMMT receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
SMMT has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-387.8%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
SMMT's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
SMMT's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-387.8%, negative) and free-cash-flow growth (-127.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 17.1% (soft) and 19.3% of outstanding shares are publicly tradable (soft). Insider ownership of 81.01% supports management-shareholder alignment.

Top 5 Institutional Investors

Baker Bros Advisors LP 4.10%
FMR Inc 1.26%
State Street Corp 1.19%
BlackRock Inc 1.19%
Vanguard Capital Management, LLC 0.72%

Unit Economics (Per $1K Revenue)

★★★★★
SMMT generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SMMT has a large-cap, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilityLarge / Mega Cap StabilityShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Oncology Research & DevelopmentClinical trial development and potential future commercialization of ivonescimab.The company is a clinical-stage biotech; it earns no significant revenue currently and relies on investor capital to fund the development of its pipeline.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 3.72
Enterprise Value 11.45B
Price to Sales(TTM) 3891.31
Enterprise Value 11.45B
Price to Sales(TTM) 3891.31
Enterprise Value to Revenue 6425.28
Enterprise Value to EBITDA -5.32
Shares Outstanding 799.76M
Shares Floating 154.30M
Shares Outstanding 799.76M
Shares Floating 154.30M
Percent Insiders 81.01
Percent Institutions 17.07

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.